Affiliation:
1. National Medical Research Centre of Oncology n.a. N.N. Blokhin
2. National Medical Research Centre of Oncology n.a. N.N. Blokhin; Russian National Research Medical University n.a. N.I. Pirogov
Abstract
Elderly cancer patients represent a very heterogeneous pop ulation not only in chronological age, but also in functional status, concomitant diseases and therapy, geriatric syndromes and, as a consequence, in the tolerability of cancer treatment. The choice of chemotherapy (CT) for metastatic breast cancer in this category of patients is often a challenge for oncologists. Eribulin, a drug with a fairly good tolerance, has proven itself well both in randomized trials and in real clinical practice, including older patient population. Pooled analyzes of several studies have shown that the incidence of hematologic adverse events in elderly patients treated with eribulin does not exceed that in younger patients and does not generally affect the planned volume of treatment. At the same time, the elderly are more likely to experience side effects such as weakness, fatigue and polyneuropathy, which must be taken into account when planning CT. Only a comprehensive multidisciplinary approach with a geriatric assessment will make it possible to maximally individualize the approach to the treatment of this difficult category of patients.
Subject
Materials Chemistry,Economics and Econometrics,Media Technology,Forestry
Reference32 articles.
1. The Surveillance, Epidemiology, and End Results (SEER) Program. SEER212013–2017, All Races, Females. Available at: https://seer.cancer.gov/statfacts/html/breast.html Accessed at October 19, 2020.
2. Bastiaannet E, Liefers GJ, de Craen AJ et al. Breast cancer in elderly compared to younger patients in the Netherlands: stage at diagnosis, treatment and survival in 127,805 unselected patients. Breast Cancer Res Treat. 2010 Dec; 124 (3): 801–7.
3. van de Water W, Markopoulos C, van de Velde CJ et al. Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer. JAMA. 2012 Feb 8; 307 (6): 590–7.
4. Bastiaannet E, Portielje JE, van de Velde CJ et al. Lack of survival gain for elderly women with breast cancer. Oncologist. 2011; 16 (4): 415–23.
5. Bouchardy C, Rapiti E, Blagojevic S et al. Older female cancer patients: importance, causes, and consequences of undertreatment. J Clin Oncol. 2007 May 10; 25 (14): 1858–69.